Walgreens Boots Alliance, Inc. (NASDAQ:WBA) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $5.40-5.70 for the period, compared to the Thomson Reuters consensus estimate of $5.47.
Shares of Walgreens Boots Alliance, Inc. (WBA) traded up $1.45 on Friday, reaching $70.99. The company had a trading volume of 12,380,900 shares, compared to its average volume of 5,343,083. Walgreens Boots Alliance, Inc. has a 1 year low of $63.82 and a 1 year high of $88.00. The company has a quick ratio of 0.59, a current ratio of 1.07 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $70,204.04, a price-to-earnings ratio of 13.64, a price-to-earnings-growth ratio of 1.24 and a beta of 1.20.
Walgreens Boots Alliance (NASDAQ:WBA) last issued its quarterly earnings results on Wednesday, October 25th. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.10. Walgreens Boots Alliance had a return on equity of 18.36% and a net margin of 3.45%. The firm had revenue of $30.15 billion for the quarter, compared to analyst estimates of $29.93 billion. During the same period in the previous year, the company posted $1.07 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. equities research analysts expect that Walgreens Boots Alliance, Inc. will post 5.55 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Monday, November 13th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, November 10th. This represents a $1.60 annualized dividend and a dividend yield of 2.25%. Walgreens Boots Alliance’s dividend payout ratio is currently 42.33%.
Walgreens Boots Alliance announced that its board has authorized a stock repurchase plan on Wednesday, October 25th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the pharmacy operator to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its stock is undervalued.
Several research firms have recently weighed in on WBA. Royal Bank of Canada began coverage on Walgreens Boots Alliance in a research note on Tuesday, September 19th. They issued an outperform rating and a $96.00 price objective on the stock. Needham & Company LLC reiterated a buy rating and issued a $94.00 price objective on shares of Walgreens Boots Alliance in a research note on Saturday, September 16th. BidaskClub lowered Walgreens Boots Alliance from a hold rating to a sell rating in a research note on Tuesday, September 12th. Jefferies Group LLC reiterated a buy rating and issued a $95.00 price objective on shares of Walgreens Boots Alliance in a research note on Thursday, September 7th. Finally, UBS AG reiterated a buy rating and issued a $96.00 price objective (down from $97.00) on shares of Walgreens Boots Alliance in a research note on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of Buy and an average price target of $87.63.
In other news, Director William C. Foote sold 2,736 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $67.37, for a total value of $184,324.32. Following the transaction, the director now owns 16,415 shares of the company’s stock, valued at approximately $1,105,878.55. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John Anthony Lederer purchased 20,000 shares of the business’s stock in a transaction dated Thursday, October 26th. The stock was bought at an average cost of $67.00 per share, for a total transaction of $1,340,000.00. Following the purchase, the director now owns 50,000 shares in the company, valued at $3,350,000. The disclosure for this purchase can be found here. Corporate insiders own 13.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Walgreens Boots Alliance, Inc. (WBA) Issues FY18 Earnings Guidance” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/11/walgreens-boots-alliance-inc-wba-updates-fy18-earnings-guidance.html.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.